Endtidal Carbon Dioxide for Earlier Detection of Pulmonary Hypertension
Launched by UNIVERSITY OF GIESSEN · Dec 22, 2017
Trial Information
Current as of November 08, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
EARLIER is a forward-looking study from the University of Giessen in Germany that explores whether a simple breath test can help diagnose pulmonary hypertension (high blood pressure in the lungs) without needing invasive tests right away. Researchers will measure end-tidal CO2 (the amount of carbon dioxide in the air you exhale) using a capnography device. The goal is to find a CO2 cut-off value that can distinguish people with pulmonary hypertension from those without, making diagnosis cheaper and easier.
Who can participate? Adults 18 and older who are suspected of having pulmonary hypertension and are planned for or have already had a right heart catheterization (a standard, more invasive test) at the University Clinic Giessen. There are no listed exclusion criteria. The study is observational, meaning participants won’t receive new treatments as part of the trial; instead, the breath test is added to the usual care during the catheterization. The study is currently enrolling by invitation, aims to enroll up to about 500 people, and is led by researchers at the University of Giessen.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \> 18 years, suspicion of pulmonary hypertension, planned or accomplished right heart catheterization
- Exclusion Criteria:
- • none
About University Of Giessen
The University of Giessen, a prominent research institution in Germany, is dedicated to advancing medical science through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in various fields, including medicine, pharmacology, and public health, to conduct rigorous studies aimed at improving patient outcomes. Committed to maintaining the highest ethical standards and regulatory compliance, the University of Giessen fosters a research environment that encourages scientific inquiry and the translation of findings into clinical practice, ultimately contributing to the advancement of healthcare and therapeutic strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Giessen, Hessen, Germany
Patients applied
Trial Officials
Henning Gall, MD, PhD
Principal Investigator
University Clinic Giessen and Marburg - Campus Giessen
Werner Seeger, Prof.
Study Director
University Clinic Giessen and Marburg
Ardeschir Ghofrani, Prof.
Study Director
University Clinic Giessen and Marburg
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials